Thus, despite BRAF mutated tumors, which can be efficiently treated with combination ICI therapy and/or targeted approaches, little progress has been made in identifying effective therapeutic options for the treatment of patients with wild-type BRAF melanomas (53). The gene discussed is BRAF; the disease is melanoma.